Literature DB >> 25633615

Evaluation of choroidal thickness using spectral-domain optical coherence tomography in patients with migraine: a comparative study.

Aylin Karalezli1, Guner Celik, Bengu Ekinci Koktekir, Cem Kucukerdonmez.   

Abstract

PURPOSE: To assess choroidal thickness in patients with migraine and compare them with healthy controls, using spectral-domain optical coherence tomography (OCT).
METHODS: In this prospective case-control study, choroidal thicknesses of 20 newly diagnosed migraine patients and 20 age- and sex-matched healthy subjects were measured using a high-speed, high-resolution frequency domain (FD) OCT device (λ = 840 nm, 26.000 A-scans/s, 5 µm axial resolution). All patients underwent a complete ophthalmic examination before the measurements. OCT measurements were taken at the same time of day (9:00 AM), in order to minimize the effects of diurnal variation.
RESULTS: There was a statistically significant difference in median choroidal thickness between the migraine patients (277.00 [interquartile range (IQR) 85.75] µm) and controls (301.00 [IQR 90.50] µm) (p = 0.012). There were significant differences at all measurement points (p<0.05 for all).
CONCLUSIONS: The decreased choroidal thickness of patients with migraine might be related to the vascular pathology of the disease. Further studies are needed to evaluate the etiopathologic relationship between choroidal thickness and migraine.

Entities:  

Mesh:

Year:  2015        PMID: 25633615     DOI: 10.5301/ejo.5000561

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  2 in total

1.  Choroidal thickness measurements in migraine patients during attack-free period.

Authors:  Emine Esra Karaca; Emine Belgin Koçer; Şengül Özdek; Hanife Tuba Akçam; Merve Bahar Ercan
Journal:  Neurol Sci       Date:  2015-08-15       Impact factor: 3.307

2.  Changes in retinal vessel diameters in migraine patients during attack-free period.

Authors:  Metin Unlu; Duygu Gulmez Sevim; Murat Gultekin; Recep Baydemir; Cagatay Karaca; Ayse Oner
Journal:  Int J Ophthalmol       Date:  2017-03-18       Impact factor: 1.779

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.